These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 15983299)

  • 21. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice.
    Gegick CG; Altheimer MD
    Endocr Pract; 2001; 7(3):162-9. PubMed ID: 11421562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes.
    Peters Harmel AL; Kendall DM; Buse JB; Boyle PJ; Marchetti A; Lau H
    Curr Med Res Opin; 2004; 20(2):215-23. PubMed ID: 15006017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study.
    Chappuis B; Braun M; Stettler C; Allemann S; Diem P; Lumb PJ; Wierzbicki AS; James R; Christ ER
    Diabetes Metab Res Rev; 2007 Jul; 23(5):392-9. PubMed ID: 17211855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia.
    Deeg MA; Buse JB; Goldberg RB; Kendall DM; Zagar AJ; Jacober SJ; Khan MA; Perez AT; Tan MH;
    Diabetes Care; 2007 Oct; 30(10):2458-64. PubMed ID: 17595355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Study of Effects of Pioglitazone and Rosiglitazone on Various Parameters in Patients of Type-2 Diabetes Mellitus with Special Reference to Lipid Profile.
    Sharma SK; Verma SH
    J Assoc Physicians India; 2016 Sep; 64(9):24-28. PubMed ID: 27762511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm.
    Saad MF; Greco S; Osei K; Lewin AJ; Edwards C; Nunez M; Reinhardt RR;
    Diabetes Care; 2004 Jun; 27(6):1324-9. PubMed ID: 15161783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of pioglitazone in modifying the atherogenic lipoprotein profile.
    Hanefeld M
    Diabetes Obes Metab; 2009 Aug; 11(8):742-56. PubMed ID: 19519869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus.
    Freed MI; Ratner R; Marcovina SM; Kreider MM; Biswas N; Cohen BR; Brunzell JD;
    Am J Cardiol; 2002 Nov; 90(9):947-52. PubMed ID: 12398960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy.
    Berhanu P; Perez A; Yu S
    Diabetes Obes Metab; 2007 Jul; 9(4):512-20. PubMed ID: 17587394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.
    Aronoff S; Rosenblatt S; Braithwaite S; Egan JW; Mathisen AL; Schneider RL
    Diabetes Care; 2000 Nov; 23(11):1605-11. PubMed ID: 11092281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The long-term effects of rosiglitazone on serum lipid concentrations and body weight.
    Shim WS; Do MY; Kim SK; Kim HJ; Hur KY; Kang ES; Ahn CW; Lim SK; Lee HC; Cha BS
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):453-9. PubMed ID: 16984237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients.
    Oz Gul O; Tuncel E; Yilmaz Y; Ulukaya E; Gul CB; Kiyici S; Oral AY; Guclu M; Ersoy C; Imamoglu S
    Metabolism; 2010 Jan; 59(1):64-9. PubMed ID: 19709689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes.
    Vijay SK; Mishra M; Kumar H; Tripathi K
    Acta Diabetol; 2009 Mar; 46(1):27-33. PubMed ID: 18758684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes.
    Berneis K; Rizzo M; Stettler C; Chappuis B; Braun M; Diem P; Christ ER
    Expert Opin Pharmacother; 2008 Feb; 9(3):343-9. PubMed ID: 18220486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones.
    Florkowski CM
    Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones.
    Oz O; Tuncel E; Eryilmaz S; Fazlioglu M; Gul CB; Ersoy C; Ocak N; Dirican M; Cangur S; Baran I; Imamoglu S
    Endocrine; 2008 Feb; 33(1):101-5. PubMed ID: 18392690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?
    Doggrell SA
    Expert Opin Pharmacother; 2008 Feb; 9(3):405-20. PubMed ID: 18220491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
    Wolffenbuttel BH; Gomis R; Squatrito S; Jones NP; Patwardhan RN
    Diabet Med; 2000 Jan; 17(1):40-7. PubMed ID: 10691158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus.
    Göke B;
    Treat Endocrinol; 2002; 1(5):329-36. PubMed ID: 15832486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.
    Perségol L; Duvillard L; Monier S; Brindisi MC; Bouillet B; Petit JM; Vergès B
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E2015-9. PubMed ID: 25137425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.